Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II, proof-of-concept trial of RX 3117 in patients with pancreatic cancer.

Next Previous
X
Search
Trial Profile

A phase I/II, proof-of-concept trial of RX 3117 in patients with pancreatic cancer.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roducitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 05 Nov 2020 According to an Ocuphire Pharma media release, Ocuphire Pharma has acquired Rexahn Pharmaceuticals. The combined company is named as Ocuphire Pharma.
    • 11 Sep 2017 According to a Rexahn Pharmaceuticals media release, initial data readout from stage 2 of this trial is expected 4Q 2017.
    • 20 Jan 2017 According to Rexahn Pharmaceuticals media release, stage 2 of this trial is ongoing and an initial data readout is expected late in 2/3Q 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top